Background No studies have directly compared the effectiveness and safety of dabigatran
and rivaroxaban using US Medicare data. Objective Our objective was to compare …

BACKGROUND: Few studies have assessed adherence to non-vitamin K antagonist oral
anticoagulants (NOACs), especially using contemporary data now that multiple NOACs are …

Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …

Aim Direct oral anticoagulants (DOACs) have shown noninferiority to warfarin for stroke
prevention in nonvalvular atrial fibrillation (AF) and a more promising safety profile …

The aim of our article is to provide a concise review for clinicians entailing the main studies
that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for …

Background Non-vitamin K dependent oral anticoagulants (NOACs) significantly decrease
overall major bleeding rates compared with vitamin K antagonists (VKAs) but there is …

Objective: To conduct a systematic review of real-world (RWD) studies comparing the risk of
major bleeding (MB) among patients with non-valvular atrial fibrillation (NVAF) on direct oral …

Background Persistence to treatment affects clinical outcomes in patients with chronic
disease such as atrial fibrillation (AF). Methods This prospective cohort study included …

Background Most comparisons of bleeding patients who are taking warfarin or a non–
vitamin K oral anticoagulant (NOAC) have been limited to admitted patients and major …

Anticoagulant medications are frequently used to prevent and treat thromboembolic disease.
However, the benefits of anticoagulants must be balanced with a careful assessment of the …